Adverse Events Associated With the Use of Sipuleucel-T Reported to the US Food and Drug Administration’s Adverse Event Reporting System, 2010-2017

IMPORTANCE: Sipuleucel-T was the first therapeutic cancer vaccine approved by the US Food and Drug Administration (FDA) in 2010. Although almost a decade has passed since its approval for the treatment of asymptomatic or minimally symptomatic castration-resistant prostate cancer (CRPC), there remain...

Full description

Saved in:
Bibliographic Details
Published in:JAMA Netw Open
Main Authors: Dores, Graça M., Bryant-Genevier, Marthe, Perez-Vilar, Silvia
Format: Artigo
Language:Inglês
Published: American Medical Association 2019
Subjects:
Original Investigation
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6694390/
https://ncbi.nlm.nih.gov/pubmed/31411714
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamanetworkopen.2019.9249
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items